
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
The American Society of Hematology is launching a health equity effort, "Treating Fairly," which was discussed at the quality symposium at the 66th Annual Meeting & Exposition.
Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.
Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.
There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.